<?xml version="1.0" encoding="UTF-8"?>
<ref id="pone.0229239.ref022">
 <label>22</label>
 <mixed-citation publication-type="journal">
  <name>
   <surname>Poordad</surname>
   <given-names>F</given-names>
  </name>, 
  <name>
   <surname>Pol</surname>
   <given-names>S</given-names>
  </name>, 
  <name>
   <surname>Asatryan</surname>
   <given-names>A</given-names>
  </name>, 
  <name>
   <surname>Buti</surname>
   <given-names>M</given-names>
  </name>, 
  <name>
   <surname>Shaw</surname>
   <given-names>D</given-names>
  </name>, 
  <name>
   <surname>Hézode</surname>
   <given-names>C</given-names>
  </name>, 
  <etal>et al</etal>
  <article-title>Glecaprevir/Pibrentasvir in patients with hepatitis C virus genotype 1 or 4 and past direct-acting antiviral treatment failure</article-title>. 
  <source>Hepatol Baltim Md</source>. 
  <year>2018</year>;
  <volume>67</volume>(
  <issue>4</issue>):
  <fpage>1253</fpage>–
  <lpage>60</lpage>.
 </mixed-citation>
</ref>
